Zai Lab Announces Early Completion of Enrollment for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
86
Zai Lab Announces Early Completion of Enrollment for ZL-2306 PK Study

SHANGHAI, China, May 21, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB ), a Shanghai-based innovative biopharmaceutical company, today announced that it has completed enrollment ahead of schedule of the pharmacokinetics (PK) study for ZL-2306 for Chinese patients with platinum-sensitive ovarian cancer. ZL-2306 is a highly potent and selective oral, once-daily small molecule poly (ADP-ribose) polymerase 1/2, or PARP 1/2, inhibitor with the potential to be a first-in-class category 1 drug for treatment across multiple solid tumor types in China.

“We are pleased that our pharmacokinetics study, initiated in late 2017 with the purpose of establishing the PK profile of ZL-2306 in Chinese patients, has successfully completed enrollment three months ahead of schedule,” said Samantha Du, Zai Lab’s Chief Executive Officer. “We expect to finalize the data from this study by mid-2018, also earlier than planned, and look forward to continuing our active dialogue with the regulatory authorities to bring ZL-2306 to Chinese patients with ovarian cancer as quickly as possible.” In China the current standard of care to treat ovarian cancer consists of radical surgery and chemotherapy.

About ZL-2306 ZL-2306 (niraparib) is a highly potent and selective oral, once-daily small molecule poly (ADP-ribose) polymerase 1/2, or PARP 1/2, inhibitor. Niraparib was approved in March 2017 by the FDA in the US and in November 2017 by EMA in EU under the trade name ZEJULA ® , as a maintenance treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Based on approval status in the US and EU, Zai Lab recently submitted market registration application for ZL-2306 in Hong Kong and plans to launch and commercialize ZL-2306 in Hong Kong in the second half of 2018. Zai Lab believes ZL-2306 has the potential to be a first-in-class category 1 drug for treatment across multiple solid tumor types in China.

About Zai Lab Zai Lab (NASDAQ: ZLAB ) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.

Zai Lab Forward-Looking Statements This press release includes certain disclosures which contain "forward-looking statements," including, without limitation, statements regarding the timing of commercialization of ZL-2306. You can identify forward-looking statements because they contain words such as "anticipate" and "expected." Forward-looking statements are based on Zai Lab's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Zai Lab's Annual Report on Form 20-F for the fiscal year ended December 31, 2017, and its other filings with the Securities and Exchange Commission. Zai Lab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact:

Zai Lab Billy Cho +86 137 6151 2501 billy.cho@zailaboratory.com

Media: Justin Jackson Burns McClellan, on behalf of Zai Lab 212-213-0006, ext. 327, jjackson@burnsmc.com

Investors: Jill Steier Burns McClellan, on behalf of Zai Lab 212-213-0006, ext. 367, jsteier@burnsmc.com  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 292

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 206

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Lululemon Faces Class Action: Navigating Investor Impact

Updated Category News Views 138

Lululemon's Legal Storm: Understanding the Background If you thought the yoga gear game was all about stretch and flexibility, Lululemon Athletica, Inc (NASDAQ: LULU) just yanked us back to reality. The company finds itself in a legal tangle with its shareholders following a dismal performance report and a subsequent lawsuit. This situation has unfolded like a second-rate...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 237

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 121

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 189

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading

Top 5 Most Recently Viewed Articles

Cobre del Mayo Initiates Exchange Offer for New Notes

Updated Category News Views 154

Cobre del Mayo Launches Exchange Offer Cobre del Mayo, S.A. de C.V. ("CDM") has announced an exciting exchange offer aimed at providing opportunities for Eligible Holders. This initiative involves exchanging all outstanding Senior Secured PIK Toggle Notes due 2030 for new Senior Secured PIK Toggle Notes due in 2032. Understanding the Exchange Offer The exchange offer is...

Continue Reading
Valuable Michael Jordan Card Discovery Shakes Sports Collectors

Updated Category News Views 159

Remarkable Discovery of Michael Jordan Cards An extraordinary find of over 500 valuable Michael Jordan basketball cards has recently taken the sports world by storm. This discovery adds significant excitement to the sports card market, which has seen a resurgence in interest among collectors and enthusiasts alike. How the Collection Was Found The rare cards were unearthed...

Continue Reading
Foxconn Achieves Record Revenue Due to Strong AI Demand

Updated Category News Views 228

Foxconn's record third quarter performance hit the headlines back in 2024, with a staggering revenue of T$1.85 trillion ($57.3 billion). This marked a significant 20.2% surge from the previous year—one for the books, right? It not only eclipsed analyst estimates but also smashed Foxconn's own projections. You know these desks were buzzing after hearing those figures...

Continue Reading
Worlds Inc. Uplists to OTCQB, Enhancing Market Presence and Value

Updated Category News Views 69

Worlds Inc. Uplists to OTCQB for Enhanced Market Visibility Boston, MA — Worlds Inc. (OTCQB: WDDD) has reached an important milestone by moving up from the OTC Pink Market to the OTCQB Venture Market. This transition is set to improve trading visibility and liquidity, effective immediately. New Strategic Opportunities Ahead Thom Kidrin, the CEO of Worlds Inc., shared...

Continue Reading
Mercer International's Strong Q3 Performance and Dividend Update

Updated Category News Views 109

Mercer International Inc. Reports Third Quarter 2024 Results Selected Highlights Operating EBITDA for Q3 rose by 35% to $50.5 million (net loss of $17.6 million), up from $37.5 million (net loss of $26.0 million) year-over-year. Strength noted in softwood pulp markets. Pulp production was affected by unplanned downtime events. Quarterly cash dividend announced at $0.075

Continue Reading